In the growing number of patients with renal failure from diabetic nephropathy (1) , CAPO offers definite advantages. It provides continuous control of fluid status and hypertension without inducing haemodynamic instability, maintains steady state levels of metabolites, avoids the need for vascular access and systemic heparinisation, and may retard the progression of neuropathy (2, 3) . A further advantage of CAPO is that glycaemic control can be improved with intraperitoneal (IP) administration of insulin via the indwelling peritoneal catheter (3) (4) (5) (6) . At present 26% of all patients beginning CAPO in the U.S.A. have diabetic nephropathy (7) . Although some authorities still advocate subcutaneous insulin in these patients (8) , we believe that the intraperitoneal route has definite advantages and will become increasingly used.
All endogenous insulin secreted by the pancreas reaches the liver by the portal vein and 50% of portal venous insulin is extracted by the liver before entering the systemic circulation (9) . This relatively high concentration of insulin in the liver modulates the metabolism of absorbed nutrients before they enter the systemic circulation and may be important in glucose homeostasis (10) . Insulin given intraperitoneally is absorbed mainly by diffusion into the portal venous circulation and directly through the capsule of the liver (11) . It thus simulates physiological insulin secretion more closely than systemic insulin (12) . IP insulin can also reach the systemic circulation directly by diffusion across the parietal peritoneum and by convective transfer via the peritoneal cavity lymphatics (13) .
The absorption kinetics of IP administration of regular insulin promote glycaemic control throughout the dwell time; IP insulin is absorbed along with the obligatory glucose load from the dialysate and insulin absorption continues until the end of the dwell (Fig.  1 ). Intraperitoneal insulin is rapidly absorbed and has been detected in the peripheral blood within 15 min-The International Journal Of Artificial Organs / Vol. 11 / no. 1, 1988/ pp. 9-12 utes of administration (12) . The rate of IP insulin absorption depends on the transperitoneal concentration gradient (14) , but is unaltered by the osmolality of the dialysis solution or the ultrastructure of the diabetic peritoneum (6). Thus, peak serum insulin levels are observed 30-45 minutes after administration into an empty peritoneal cavity (12) and delayed until 90-120 minutes when insulin is added to the dialysate (15) . Although insulin absorption from the dialysate solution reservoir continues for at least 6 hours after the peak serum insulin level is reached (15) , only 50% of insulin instilled into the peritoneal cavity is absorbed after an 8 hour dwell time (4, 6) . Degradation of the insulin remaining within the peritoneal cavity has not been observed (15) . Insulin antibodies have been shown to decrease transperitoneal insulin transport in-vitro (16, 17) , but the clinical significance of this observation is uncertain.
After absorption from the peritoneal cavity 50% of biologically active, portal venous insulin is removed during first pass through the liver, and so absorption kinetics and efficacy of IP and systemic insulin cannot be compared by measurement of peripheral blood insulin levels. The hypoglycaemic response observed with insulin infused into an empty peritoneal cavity was greater than with the same dose of subcutaneous insulin even though peripheral blood insulin levels were lower (12) . This economic utilisation of absorbed IP insulin in the liver without first increasing insulin levels in the peripheral blood is potentially of benefit since hyperinsulinaemia has been implicated in the pathogenesis of accelerated atherogenesis observed in diabetic patients on systemic insulin therapy (18) .
A further advantage of IP insulin is that subcutaneous injections can be avoided and insulin prescribed four times per day with good patient compliance. The concern that injection of insulin into the peritoneal dialysis system would increase the rate of peritonitis has not been substantiated (3, 5, 7, 19) . The further training required for diabetic CAPO patients in the use of IP insulin may improve expertise in aseptic technique or IP insulin may bacteriostatic. The addition of IP insulin has no effect on solute clearances, ultrafiltration volume or glucose absorption from the dialysis solution (20) and sclerosing peritonitis has not been associated with the use of IP drug additives.
The additional glucose load (80-250 g/day) ab- moglobin (HbAic) < 9%, and avoidance of hypoglycemia have been achieved with IP insulin administration (3). Indeed, glycosylated haemoglobin levels were similar in diabetic and non-diabetic patients on CAPD (3) . Although interference of carbamylated haemoglobin with the chromatographic, HbA 1c assay was probably equivalent in both uraemic groups (25) , insulin resistance in target tissues in uraemia is only partially corrected by dialysis (26) and may have contributed to impaired glucose tolerance in the non-diabetic group. Despite these limitations, HbA 1c levels remain a useful adjunct to finger prick blood glucose measurements in assessing longer term glycaemic control. Recent studies have shown improved blood glucose control in diabetic CAPD patients using IP insulin added to the dialysis solution compared with control while on subcutaneous insulin before begin-sorbed from the dialysate increases insulin requirements. Incomplete absorption (less than 50%) of intraperitoneally delivered insulin further increases the required daily dose of insulin. Despite great variation (18-284 units/day) in IP insulin requirements of diabetic CAPD patients (5) , the daily IP insulin dose is usually more than double the pre-CAPD daily subcutaneous dose (5, 6) . Hence 150% of the pre-CAPD or 100% of all CAPD daily subcutaneous insulin dose can be safely divided among all four exchanges, with a reduced insulin dose added to the overnight dwell to avoid nocturnal hypoglycaemia. IP insulin therapy must be individualized and review of morning "fasting", 2 hour post-prandial, and pre-exchange blood glucose results of the previous day allows step-wise changes in insulin added to each cycle until desired blood glucose control is achieved. Each peritoneal dialysis exchange with IP insulin should be performed before meals to promote peak insulin absorption at the time of food intake and so minimise meal related hyperglycaemia. Strict aseptic technique using a long needle should be used to add insulin to the dialysate through the injection port. If blind diabetics are unable to use an lnjecta-Aid, a partner or nurse can premix insulin with the dialysate for up to 24 hours without significant insulin adsorption to the plastic bags (21) . Increments in insulin are required for each additional hypertonic dialysis cycle incorporated into the daily routine. IP insulin requirements during episodes of peritonitis are often believed to be increased (22, 23) , but hypoglycaemia has also been reported when the usual dose of IP insulin was continued during peritonitis (24) . Blood glucose during peritonitis is likely to be determined by the relative importance of increased insulin absorption and reduced carbohydrate intake due to anorexia versus increased glucose absorption and infection related catabolic state. This emphasises the need for follow-up monitoring of blood glucose and subsequent modification of insulin dosage, especially during changes in the patient's routine. Intraperitoneal insulin therapy has been shown to reduce the mean glucose level (4), meal-related hyperglycaemia (12) and daily glucose excursions (6) when compared with subcutaneous insulin. In diabetic CAPD patients such treatment objectives as maintaining morning "fasting" glucose < 140 mg/dl, postmeal hyperglycaemia < 200 mg/dl, glucosylated hae-ning dialysis (3) (4) (5) . Others have demonstrated good glycemic control with insulin injected directly into the tubing and flushed into an empty peritoneal cavity with a small volume of dialysate (23, 27) , but whether this modification further improves blood glucose control remains uncertain. Improved glycemic control is the major benefit of IP insulin in diabetic CAPO patients and may delay or halt further progression of the microvascular complications of diabetes (28) . Indeed the advantages of IP insulin administration have prompted the use of IP insulin in non-dialysis dependent diabetic patients with encouraging results (29, 30) . For the diabetic in renal failure, meanwhile, intraperitoneal insulin may well become the treatment of choice.
